Niall C Tebbutt

Loading... 2 0 20 0 false
Credit Name
Niall C Tebbutt
Full Name
Tebbutt, Niall C
 
 
Loading... 3 0 20 0 false

Publications

Results 41-60 of 117 (Search time: 0.013 seconds).

Publication YearTitleAuthor(s)
4129-Jan-2021Dual anti-angiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study.Mooi, Jennifer K ; Chionh, Fiona; Savas, Peter; Da Gama Duarte, Jessica; Chong, Geoffrey ; Brown, Stephen; Wong, Rachel; Price, Timothy; Wann, Alysson ; Skrinos, Effie; Mariadason, John M ; Tebbutt, Niall C 
421-Jan-2021Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.Schmoll, Hans-Joachim; Stein, Alexander; Van Cutsem, Eric; Price, Timothy; Hofheinz, Ralf D; Nordlinger, Bernard; Daisne, Jean-François; Janssens, Jos; Brenner, Baruch; Reinel, Hans; Hollerbach, Stephan; Caca, Karel; Fauth, Florian; Hannig, Carla V; Zalcberg, John; Tebbutt, Niall C ; Mauer, Murielle E; Marreaud, Sandrine; Lutz, Manfred P; Haustermans, Karin
432021Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group.Dunn, Catherine; Hong, Wei; Gibbs, Peter; Ackland, Stephen; Sjoquist, Katrin; Tebbutt, Niall C ; Price, Timothy; Burge, Matthew
441-Nov-2020Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA.Gulhati, Pat; Yin, Jun; Pederson, Levi; Schmoll, Hans-Joachim; Hoff, Paulo; Douillard, Jean-Yves; Hecht, J Randolph; Tournigand, Christophe; Tebbutt, Niall C ; Chibaudel, Benoist; Gramont, Aimery De; Shi, Qian; Overman, Michael James
451-Sep-2020Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.Klein, Oliver ; Kee, Damien ; Nagrial, Adnan; Markman, Ben; Underhill, Craig; Michael, Michael; Jackett, Louise A ; Lum, Caroline; Behren, Andreas; Palmer, Jodie ; Tebbutt, Niall C ; Carlino, Matteo S; Cebon, Jonathan S 
4620-Apr-2020Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.Roy, Amitesh C; Shapiro, Jeremy; Burge, Matt; Karapetis, Christos S; Pavlakis, Nick; Segelov, Eva; Chau, Ian; Lordick, Florian; Chen, Li-Tong; Barbour, Andrew; Tebbutt, Niall C ; Price, Tim
47Apr-2020Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO Congress 2019.Lau, David K ; Burge, Matthew; Roy, Amitesh; Chau, Ian; Haller, Daniel G; Shapiro, Jeremy D; Peeters, Marc; Pavlakis, Nick; Karapetis, Christos S; Tebbutt, Niall C ; Segelov, Eva; Price, Timothy J
4819-Mar-2020Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients with Elevated CEA.Gulhati, Pat; Yin, Jun; Pederson, Levi; Schmoll, Hans-Joachim; Hoff, Paulo; Douillard, Jean-Yves; Hecht, J Randolph; Tournigand, Christophe; Tebbutt, Niall C ; Chibaudel, Benoist; De Gramont, Aimery; Shi, Qian; Overman, Michael James
49Mar-2020Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.Williams, David S ; Mouradov, Dmitri; Browne, Clare; Palmieri, Michelle; Elliott, Meg J; Nightingale, Rebecca; Fang, Catherine G; Li, Rita; Mariadason, John M ; Faragher, Ian; Jones, Ian T; Churilov, Leonid ; Tebbutt, Niall C ; Gibbs, Peter; Sieber, Oliver M
502020The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].Clarke, Stephen John; Burge, Matthew; Feeney, Kynan; Gibbs, Peter; Jones, Kristian; Marx, Gavin; Molloy, Mark P; Price, Timothy; Reece, William H H; Segelov, Eva; Tebbutt, Niall C 
5122-Nov-2019Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets.Lau, David K ; Mouradov, Dmitri; Wasenang, Wiphawan; Luk, Ian Y; Scott, Cameron M; Williams, David S ; Yeung, Yvonne H ; Limpaiboon, Temduang; Iatropoulos, George F ; Jenkins, Laura J; Reehorst, Camilla M; Chionh, Fiona; Nikfarjam, Mehrdad ; Croagh, Daniel; Dhillon, Amardeep S; Weickhardt, Andrew J ; Muramatsu, Toshihide; Saito, Yoshimasa; Tebbutt, Niall C ; Sieber, Oliver M; Mariadason, John M 
524-Sep-2019Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.Burzykowski, Tomasz; Coart, Elisabeth; Saad, Everardo D; Shi, Qian; Sommeijer, Dirkje W; Bokemeyer, Carsten; Díaz-Rubio, Eduardo; Douillard, Jean-Yves; Falcone, Alfredo; Fuchs, Charles S; Goldberg, Richard M; Hecht, J Randolph; Hoff, Paulo M; Hurwitz, Herbert; Kabbinavar, Fairooz F; Koopman, Miriam; Maughan, Timothy S; Punt, Cornelis J A; Saltz, Leonard; Schmoll, Hans-Joachim; Seymour, Matthew T; Tebbutt, Niall C ; Tournigand, Christophe; Van Cutsem, Eric; de Gramont, Aimery; Zalcberg, John R; Buyse, Marc
53Jun-2019Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial.Tapia Rico, Gonzalo; Price, Timothy; Tebbutt, Niall C ; Hardingham, Jennifer; Lee, Chee; Buizen, Luke; Wilson, Kate; Gebski, Val; Townsend, Amanda
5416-Apr-2019Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.Eng, Cathy; Kim, Tae Won; Bendell, Johanna; Argilés, Guillem; Tebbutt, Niall C ; Di Bartolomeo, Maria; Falcone, Alfredo; Fakih, Marwan; Kozloff, Mark; Segal, Neil H; Sobrero, Alberto; Yan, Yibing; Chang, Ilsung; Uyei, Anne; Roberts, Louise; Ciardiello, Fortunato
55Apr-2019Systemic treatment of advanced hepatocellular cancer: new hope on the horizon.Chang Lee, Rachael; Tebbutt, Niall C 
56Mar-2019Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.Wells, J Connor; Tu, Dongsheng; Siu, Lillian L; Shapiro, Jeremy D; Jonker, Derek J; Karapetis, Christos; Simes, John; Liu, Geoffrey; Price, Timothy J; Tebbutt, Niall C ; O'Callaghan, Chris J
57Dec-2018Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.Shapiro, Jeremy D; Thavaneswaran, Subotheni; Underhill, Craig R; Robledo, Kristy P; Karapetis, Christos S; Day, Fiona L; Nott, Louise M; Jefford, Michael; Chantrill, Lorraine A; Pavlakis, Nick; Tebbutt, Niall C ; Price, Timothy J; Khasraw, Mustafa; Van Hazel, Guy A; Waring, Paul M; Tejpar, Sabine; Simes, John; Gebski, Val J; Desai, Jayesh; Segelov, Eva
58Dec-2018Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.Sud, S; O'Callaghan, C ; Jonker, C; Karapetis, C; Price, T; Tebbutt, Niall C ; Shapiro, J; Van Hazel, G; Pavlakis, N; Gibbs, P; Jeffrey, M; Siu, L; Gill, S; Wong, R ; Jonker, D; Tu, D; Goodwin, R
5928-Nov-2018Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.Wells, J Connor; Tu, Dongsheng; Siu, Lillian L; Shapiro, Jeremy D; Jonker, Derek J; Karapetis, Christopher S; Simes, John; Liu, Geoffrey; Price, Timothy J; Tebbutt, Niall C ; O'Callaghan, Chris J
601-Nov-2018The prognostic impact of Consensus Molecular Subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.Mooi, Jennifer K ; Wirapati, P; Asher, R; Lee, C K; Savas, P S; Price, T J; Townsend, A; Hardingham, J; Buchanan, D; Williams, D ; Tejpar, S; Mariadason, John M ; Tebbutt, Niall C